CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Revenues	$ 1,608,022	$ 1,470,116	$ 3,119,507	$ 2,789,107
Expenses:
Research and development	529,289	509,975	1,027,875	1,017,410
Selling, general, and administrative	364,884	306,908	695,654	603,754
Total expenses	985,834	919,804	1,930,088	1,808,253
Income from operations	622,188	550,312	1,189,419	980,854
Other income (expense):
Other income (expense), net	40,804	(19,061)	65,410	(9,813)
Interest expense	(6,918)	(5,401)	(13,357)	(12,902)
Total other income (expense)	33,886	(24,462)	52,053	(22,715)
Income before income taxes	656,074	525,850	1,241,472	958,139
Income tax expense	(104,662)	(138,106)	(212,080)	(321,464)
Net income	$ 551,412	$ 387,744	$ 1,029,392	$ 636,675
Net income per share - basic (in dollars per share)	$ 5.12	$ 3.66	$ 9.56	$ 6.02
Net income per share - diluted (in dollars per share)	$ 4.82	$ 3.34	$ 8.97	$ 5.51
Weighted average shares outstanding - basic (in shares)	107,800	106,034	107,724	105,804
Weighted average shares - diluted (in shares)	114,477	116,137	114,697	115,607
Statements of Comprehensive Income
Net income	$ 551,412	$ 387,744	$ 1,029,392	$ 636,675
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on marketable securities	3,374	8,204	(7,706)	15,160
Unrealized gain on cash flow hedges	608	28	2,047	28
Comprehensive income	555,394	395,976	1,023,733	651,863
Product
Revenues:
Revenues	996,382	924,133	1,984,291	1,782,378
Expenses:
Cost of goods sold	35,950	42,133	105,193	103,386
Collaboration and contract manufacturing
Expenses:
Cost of goods sold	55,711	60,788	101,366	83,703
Sanofi | Product and service, other
Revenues:
Revenues	237,753	222,128	427,243	432,495
Bayer | Product and service, other
Revenues:
Revenues	262,863	210,355	510,791	404,294
Other | Product and service, other
Revenues:
Revenues	$ 111,024	$ 113,500	$ 197,182	$ 169,940